Recent Research Funding
The National Institutes of Health has funded our faculty members, enabling them to conduct life-changing research.
Faculty members have received funding for research on diverse subjects like psychosomatic issues, pain management, patient reporting and compliance behaviors, whole community and family roles in psychiatric conditions and treatment, and teaching strategies.
Recent funding includes:
- Strong Foundations: Intervening to Promote Co-Parenting and Reduce Father Hazardous Drinking in Expectant Parents. Kurt Dermen (Co-Investigator). National Institute on Alcohol Abuse and Alcoholism. $2,246,077. 5/1/2019-4/1/2024.
- A 26-week, Multicenter, Open-label, Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants with Schizophrenia or Bipolar I Disorder (3070-30-001), Abbvie. Steven Dubovsky (Principal Investigator). Abbvie. $150,000. 1/1/2021-12/1/2023.
- A phase II randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of 4 oral doses of BI 1358894 once daily over 12 week treatment period in patients with borderline personality disorder, Boehringer Ingelheim. Steven Dubovsky (Principal Investigator). Boehringer Ingelheim. $200,000. 1/1/2021-12/1/2023.
